%PDF-1.4
%
39 0 obj
<>
endobj
36 0 obj
<>
endobj
91 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T12:46:51Z
2024-03-29T00:24:35-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T00:24:35-07:00
application/pdf
Heather
2002-264.oct
uuid:a11f3e4d-1dd1-11b2-0a00-5e0927fd5800
uuid:a11f3e50-1dd1-11b2-0a00-6a0000000000
endstream
endobj
25 0 obj
<>
endobj
26 0 obj
<>
endobj
40 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
18 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
113 0 obj
[117 0 R]
endobj
114 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(activation-induced cytidine deaminase \(AID\), a potential RNA)Tj
0 -1.25 TD
(editing enzyme. Cell 2000;102:553-63.)Tj
-2.175 -1.25 Td
[(34.)-875 (W)79.8 (ang H, Shlomchik MJ. High af)17.8 (finity rheumatoid factor transgenic)]TJ
2.175 -1.25 Td
(B cells are eliminated in normal mice. J Immunol 1997;)Tj
0 Tw T*
[(159:1)36.9 (125-34.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(35.)-875.1 (Andonopoulos )54.8 (AP)110.7 (, Drosos )54.8 (AA, Skopouli FN, )54.8 (Acritidis NC,)]TJ
2.175 -1.25 Td
[(Moutsopoulos HM. Secondary Sjogren\222)54.8 (s syndrome in rheumatoid)]TJ
0 Tc T*
(arthritis. J Rheumatol 1987;14:1098-103.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(36.)-875.1 (Ramos-Casals M, Garcia-Carrasco M, Cervera R, et al. Hepatitis C)]TJ
0 Tc 2.175 -1.25 Td
[(virus infection mimicking primary Sjogren syndrome. )54.9 (A)-219.8 (clinical)]TJ
T*
(and immunologic description of 35 cases. Medicine 2001;80:1-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(37.)-875.1 (Kassan SS, )17.7 (Thomas )17.7 (T)73.9 (, Moutsopoulos HM, et al. Increased risk of)]TJ
0 Tc 2.175 -1.25 Td
[(lymphoma in sicca syndrome. )54.9 (Ann Intern Med 1978;54:1027-32. )]TJ
-2.175 -1.25 Td
[(38.)-875 (Board )17.8 (VHP)110.8 (. Global surveillance and control of hepatitis C. J )17.8 (V)60.1 (iral)]TJ
2.175 -1.25 Td
(Hepatitis 1999;6:35-47.)Tj
-2.175 -1.25 Td
[(39.)-875 (Dammacco F)79.8 (, Sansonno D, Piccoli C, )17.7 (T)34.9 (ucci F)74 (A, Racanelli )17.7 (V)129.2 (. )17.7 (The)]TJ
2.175 -1.25 Td
[(cryoglobulins: an overview)64.9 (. Eur J Clin Invest 2001;31:628-38. )]TJ
-2.175 -1.25 Td
[(40.)-875 (Zvaifler NJ. Etiology and pathogenesis of rheumatoid arthritis. In:)]TJ
2.175 -1.25 Td
[(McCarthy DJ, editor)54.9 (. )54.8 (Arthritis and allied conditions. 1)36.8 (1th ed.)]TJ
T*
(Philadelphia: Lea & Febiger; 1989;659.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(41.)-875.1 (Ahmed )54.8 (AS, Penhale )17.7 (W)91.7 (,)-0.1 ( )17.7 (T)69.7 (alal N. Sex hormones, immune responses,)]TJ
0 Tc 2.175 -1.25 Td
[(and autoimmune diseases. Mechanisms of sex hormone action. )54.9 (Am)]TJ
T*
(J Pathol 1985;121:531-51.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(42.)-875.1 (Cacoub P)110.7 (, Hausfater P)110.7 (, Musset L, Piette JC. Mixed)]TJ
0 Tc 2.175 -1.25 Td
[(cryoglobulinemia in hepatitis C patients. GERMIVIC. )54.8 (Ann Med)]TJ
-0.00011 Tc T*
(Interne Paris 2000;151:20-9.)Tj
-2.175 -1.25 Td
[(43.)-875.1 (W)79.7 (olfe F)79.7 (, Cathey MA, Roberts FK. )17.7 (The Latex test revisited.)]TJ
0 Tc 2.175 -1.25 Td
(Rheumatoid factor testing in 8,287 rheumatic disease patients.)Tj
T*
(Arthritis Rheum 1991;34:951-60.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(44.)-875.1 (Mattey DL, Gonzalez-Gay MA, Hajeer )54.8 (AH, et al. )54.8 (Association)]TJ
2.175 -1.25 Td
[(between HLA-DRB1*15 and secondary Sjogren\222)54.8 (s syndrome in)]TJ
0 Tc T*
[(patients with rheumatoid arthritis. J Rheumatol 2000;27:261)36.9 (1-6. )]TJ
-2.175 -1.25 Td
[(45.)-875 (Pertovaara M, Pukkala E, Laippala P)110.8 (, Miettinen )54.8 (A, Pasternack )54.8 (A. )54.8 (A)]TJ
2.175 -1.25 Td
[(longitudinal cohort study of Finnish patients with primary Sjogren\222)54.9 (s)]TJ
T*
(syndrome: clinical, immunological, and epidemiological aspects.)Tj
T*
(Ann Rheum Dis 2001;60:467-72.)Tj
-2.175 -1.25 Td
[(46.)-875 (Martin )17.8 (T)74 (, )17.8 (W)79.8 (eber J-C, Levallois H, et al. Salivary gland lymphomas)]TJ
2.175 -1.25 Td
[(in patients with Sjogren\222)54.9 (s syndrome may frequently develop from)]TJ
T*
(rheumatoid factor B cells. Blood 2000;43:908-16.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(47.)-875.1 (Katsikis PD, )36.8 (Y)100 (ouinou PY)128.8 (, Galanopoulou )17.7 (V)129.1 (, Papadopoulos NM,)]TJ
2.175 -1.25 Td
[(Tzioufoa )54.8 (AG, Moutsopoulos HM. Monoclonal process in primary)]TJ
T*
[(Sjogren\222)54.8 (s syndrome and cross-reactive idiotype associated with)]TJ
0 Tc T*
[(rheumatoid factor)54.9 (. Clin Exp Immunol 1990;82:509-14.)]TJ
-2.175 -1.25 Td
[(48.)-875 (T)34.9 (uomi )17.7 (T)74 (, )54.8 (Aho K, Palosuo )17.7 (T)74 (, et al. Significance of rheumatoid)]TJ
2.175 -1.25 Td
(factors in an eight-year longitudinal study on arthritis. Rheumatol)Tj
T*
(Int 1988;8:21-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(49.)-875.1 (Scott DL. Prognostic factors in early rheumatoid arthritis.)]TJ
0 Tc 2.175 -1.25 Td
(Rheumatology 2000;39:24-9.)Tj
-2.175 -1.25 Td
[(50.)-875 (Kim JM, )17.7 (W)79.8 (eisman MH. )17.7 (When does rheumatoid arthritis begin and)]TJ
2.175 -1.25 Td
[(why do we need to know? )54.9 (Arthritis Rheum 2000;43:473-84.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(51.)-875.1 (V)111 (an Zeben D, Hazes JMW)91.7 (, Zwinderman )54.8 (AH, Cats )54.8 (A, van der )17.7 (V)129 (oort)]TJ
0 Tc 2.175 -1.25 Td
(EAM, Breedveld FC. Clinical significance of rheumatoid factors in)Tj
-0.00011 Tc T*
[(early rheumatoid arthritis:results of a follow up study)64.8 (. )54.8 (Ann Rheum)]TJ
0 Tc T*
(Dis 1992;51:1029-35.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(52.)-875.1 (Rau R, Herborn G, Zueger S, Fenner H. )17.7 (The ef)17.7 (fect of HLA-DRB1)]TJ
0 Tc 2.175 -1.25 Td
[(genes, rheumatoid factor)39.8 (, and treatment on radiographic disease)]TJ
T*
(progression in rheumatoid arthritis over 6 years. J Rheumatol)Tj
0 Tw T*
(2000;27:2566-75.)Tj
0.02499 Tw -2.175 -1.25 Td
[(53.)-875 (Listing J, Rau R, Muller B, et al. HLA-DRB1 genes, rheumatoid)]TJ
2.175 -1.25 Td
[(factor)39.8 (, and elevated C-reactive protein: independent risk factors of)]TJ
T*
(radiographic progression in early rheumatoid arthritis. Berlin)Tj
T*
(Collaborating rheumatological Study Group. J Rheumatol)Tj
0 Tw T*
(2000;27:2100-9.)Tj
0.02499 Tw -2.175 -1.25 Td
[(54.)-875 (Aman S, Paimela L, Leirisalo-Repo M, et al. Prediction of disease)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(progression in early rheumatoid arthritis by ICTP)110.7 (, RF)79.7 (, and CRP)110.7 (. )54.8 (A)]TJ
0 Tc 33 80 Td
[(comparative 3-year follow-up study)64.9 (. Rheumatology 2000;)]TJ
0 Tw T*
(39:1009-13.)Tj
0.0249 Tw -2.175 -1.25 Td
[(55.)-875 (Kaltenhauser S, )17.7 (W)79.8 (agner U, Schuster E, et al. Immunogenetic)]TJ
2.175 -1.25 Td
(markers and seropositivity predict radiological progression in early)Tj
T*
[(rheumatoid arthritis independent of disease activity)64.9 (. J Rheumatol)]TJ
0 Tw T*
(2001;28:735-44. )Tj
0.02499 Tw -2.175 -1.25 Td
[(56.)-875 (Ohara )17.8 (T)74 (, Itoh )36.9 (Y)129.2 (, Itoh K. Reevaluation of laboratory parameters in)]TJ
2.175 -1.25 Td
[(relation to histological findings in primary and secondary Sjogren\222)54.9 (s)]TJ
T*
(syndrome. Intern Med 2000;39:457-63.)Tj
-2.175 -1.25 Td
[(57.)-875 (Cacoub P)110.8 (,)0.1 ( Poynard )17.7 (T)74 (, Ghillan P)110.8 (, et al. Extrahepatic manifestations)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(of chronic hepatitis C. MUL)91.7 (TIVIRC group. Multidepartment virus)]TJ
0 Tc T*
[(C. )54.9 (Arthritis Rheum 1999;42:2204-12.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(58.)-875.1 (Erhardt CC, Mumford P)110.7 (, Maini RN. Dif)17.7 (ferences in)]TJ
0 Tc 2.175 -1.25 Td
(immunochemical characteristics of cryoglobulins in rheumatoid)Tj
T*
(arthritis and systemic lupus erythematosus and their complement)Tj
T*
[(binding properties. )54.9 (Ann Rheum Dis 1984;43:451-6.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(59.)-875.1 (Ramos-Casals M, Garcia-Carrasco M, Cervera R, et al. Hepatitis C)]TJ
0 Tc 2.175 -1.25 Td
[(virus infection mimicking primary Sjogren syndrome. )54.9 (A)-219.8 (clinical)]TJ
T*
(and immunologic description of 35 cases. Medicine Baltimore)Tj
0 Tw T*
(2001;80:1-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(60.)-875.1 (Ollier )17.7 (WER, Silman )54.8 (AJ, Gosnell NG, et al. HLA)-220.2 (and rheumatoid)]TJ
2.175 -1.25 Td
(arthritis: an analysis of multicase families. Disease Markers)Tj
0 Tc 0 Tw T*
(1986;4:85-98.)Tj
0.02499 Tw -2.175 -1.25 Td
[(61.)-875 (Silman )54.9 (AJ, Ollier B, Mageed RA. Rheumatoid factor detection in)]TJ
2.175 -1.25 Td
[(the unaf)17.8 (fected first degree relatives in families with multicase)]TJ
T*
(rheumatoid arthritis. J Rheumatol 1991;18:512-4.)Tj
-2.175 -1.25 Td
[(62.)-875 (Balsa )54.8 (A, Barrera P)110.8 (, )17.7 (W)79.8 (esthovens R, et al. Clinical and)]TJ
2.175 -1.25 Td
(immunogenetic characteristics of European multicase rheumatoid)Tj
T*
[(arthritis families. )54.8 (Ann Rheum Dis 2001;60:573-6.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(63.)-875.1 (Pease CT)73.9 (, Shattles )17.7 (W)91.7 (, Charles PJ, )17.7 (V)111 (enables PJW)91.7 (, Maini RN.)]TJ
0 Tc 2.175 -1.25 Td
[(Clinical, serological, and HLA)-220.1 (phenotype subsets in Sjogren\222)54.9 (s)]TJ
T*
(syndrome. Clin Exp Rheumatol 1989;7:185-90.)Tj
-2.175 -1.25 Td
[(64.)-875 (Cacoub P)110.8 (, Renou C, Kerr G, et al. Influence of HLA-DR phenotype)]TJ
2.175 -1.25 Td
(on the risk of hepatitis C virus-associated mixed cryoglobulinemia.)Tj
T*
[(Arthritis Rheum 2001;44:21)36.9 (18-24.)]TJ
-2.175 -1.25 Td
[(65.)-875 (Brouet JC, Clauvel JP)110.8 (, Danon F)79.8 (, Klein M, Seligmann M. Biologic)]TJ
2.175 -1.25 Td
[(and clinical significance of cryoglobulins. )54.8 (A)-219.8 (report of 86 cases. )54.8 (Am)]TJ
T*
(J Med 1974;57:775-88.)Tj
-2.175 -1.25 Td
[(66.)-875 (Del Puente )54.8 (A, Knowler )17.7 (WC, Pettitt DJ, Bennett PH. High incidence)]TJ
2.175 -1.25 Td
[(and prevalence of rheumatoid arthritis in Pima Indians. )54.8 (Am J)]TJ
T*
[(Epidemiol 1989;129:1)36.9 (170-8.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(67.)-875.1 (Jawaheer D, )17.7 (Thomson )17.7 (W)91.7 (, MacGregor )54.8 (AJ, et al. Homozygosity for)]TJ
2.175 -1.25 Td
(the HLA-DR shared epitope contributes the highest risk for)Tj
0 Tc T*
[(rheumatoid arthritis concordance in identical twins. )54.9 (Arthritis)]TJ
T*
(Rheum 1994;37:681-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(68.)-875.1 (Cornelis F)79.7 (, Faure S, Martinez M, et al. New susceptibility locus for)]TJ
0 Tc 2.175 -1.25 Td
[(rheumatoid arthritis suggested by a genome-wide linkage study)64.9 (.)]TJ
T*
[(Proc Natl )54.8 (Acad Sci 1998;95:10746-50.)]TJ
-2.175 -1.25 Td
[(69.)-875 (Del Puente )54.8 (A, Knowler )17.7 (WC, Pettitt DJ, Bennett PH. )17.7 (The incidence)]TJ
2.175 -1.25 Td
(of rheumatoid arthritis is predicted by rheumatoid factor titer in a)Tj
T*
[(longitudinal population study)64.9 (. )54.9 (Arthritis Rheum 1988;31:1239-44.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(70.)-875.1 (Aho K, Heliovaara M, Maatela J, )17.7 (T)34.8 (uomi )17.7 (T)73.9 (, Palosuo )17.7 (T)73.9 (.)-0.1 ( Rheumatoid)]TJ
0 Tc 2.175 -1.25 Td
(factors antedating clinical rheumatoid arthritis. J Rheumatol)Tj
0 Tw T*
(1991;18:1282-4.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(71.)-875.1 (Halldorsdottir HD, Jonsson )17.7 (T)73.9 (,)-0.1 ( )17.7 (Thorsteinsson J, )17.7 (V)111 (aldimarsson H. )54.8 (A)]TJ
0 Tc 2.175 -1.25 Td
(prospective study on the incidence of rheumatoid arthritis among)Tj
T*
[(people with persistent increase of rheumatoid factor)54.9 (. )54.8 (Ann Rheum)]TJ
T*
(Dis 2000;59:149-51.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(72.)-875.1 (Jansen LMA, van der Horst-Bruinsma IE, van Schaardenbur)17.7 (g D,)]TJ
0 Tc 2.175 -1.25 Td
[(van de Stadt RJ, de Koning MHMT)74 (, Dijkmans BAC. Rheumatoid)]TJ
T*
[(factor and antibodies to cyclic citrullinated peptide dif)17.8 (ferentiate)]TJ
T*
[(rheumatoid arthritis from undif)17.8 (ferentiated polyarthritis in patients)]TJ
T*
(with early arthritis. J Rheumatol 2002;29:2074-6.)Tj
-2.175 -1.25 Td
[(73.)-875 (Zulman J, Jaf)17.8 (fe R, )17.7 (T)69.8 (alal N. Evidence that the malignant lymphoma)]TJ
2.175 -1.25 Td
[(of Sjogren\222)54.9 (s syndrome is a monoclonal B-cell neoplasm. N Engl J)]TJ
ET
0 0 0 0 scn
468 770 90 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT1 1 Tf
8 0 0 8 54.5 35.9844 Tm
(Newkirk: Editorial)Tj
0 Tw 60.9375 -0.0313 Td
(2039)Tj
ET
0 0 0 0 scn
/GS0 gs
101.25 58.05 407.5 -10.84 re
f*
0.5 w
101.25 58.05 407.5 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
78 0 obj
<>
endobj
96 0 obj
<>
endobj
45 0 obj
<>
endobj
43 0 obj
<>
endobj
44 0 obj
<>
endobj
57 0 obj
<>stream
HV lޛ]101+R.0c89@
I R"J[ TUpTE;fmD:o}?
j Ԙu cR:_Up%`> ֖TOm_MwַjZ(洙5@t>PQ/vh㝦O
"iE@TTΛ)sM@
9ď0b&J\Ki,kvN<}f͝gݦc"l}՜?dB:'h2 Z!+H k[ VP˄;XgKI[qkрHE F iwq"؆
]2XKQM\؉C8BIt8.Pk
#ިRZ F;s&L$w'N2/'Z0ew)E'@$8zar5^ a({!VaY1YS\k+E6~Qya=>G#q2bmАa; P˸
[希"BDX&>)Ureu!y٤u#?w^QOqGĉ."S2I$,y@*Ju=DNVpBMh
~ޭ#OGؙh}<p0Ud08/#e4`yAIS*e
dYlKf{ٙuz
Wۋ;{,X߸NЄ۸xD"#Z$r$76]Z,5bX*jbRf%"9I.+W<%MyW Wk|HNPkmVp~t;'8>89X